Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Other financing activities (2016 - 2025)

Adma Biologics (ADMA) has disclosed Other financing activities for 8 consecutive years, with -$2.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other financing activities changed N/A year-over-year to -$2.2 million, compared with a TTM value of $127000.0 through Dec 2025, down 94.6%, and an annual FY2023 reading of $2.4 million, down 15.52% over the prior year.
  • Other financing activities was -$2.2 million for Q4 2025 at Adma Biologics, down from $2.4 million in the prior quarter.
  • Across five years, Other financing activities topped out at $2.4 million in Q1 2022 and bottomed at -$2.2 million in Q4 2025.
  • Average Other financing activities over 3 years is $582000.0, with a median of $404562.0 recorded in 2022.
  • Peak annual rise in Other financing activities hit 3265177.78% in 2023, while the deepest fall reached 3265177.78% in 2023.
  • Year by year, Other financing activities stood at $72.0 in 2022, then skyrocketed by 3265177.78% to $2.4 million in 2023, then plummeted by 194.6% to -$2.2 million in 2025.
  • Business Quant data shows Other financing activities for ADMA at -$2.2 million in Q4 2025, $2.4 million in Q4 2023, and $72.0 in Q4 2022.